Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Frontida Biopharm, LLC
483
•Frontida Biopharm, LLC•October 24, 2025

Frontida Biopharm, LLC – FDA 483, Oct 24, 2025

Record Details

During an FDA inspection conducted from October 20-24, 2025, Frontida Biopharm, LLC, a drug manufacturer based in Aurora, IL, received an FDA Form 483. This document outlined significant observations indicating potential deviations from Current Good Manufacturing Practices (CGMP) related to the company's quality and production systems.

Key issues identified included the absence of a fully functional quality control unit with adequate responsibility and authority for approving materials, investigating production errors, managing field alert reports, and reviewing written quality procedures. Furthermore, the firm lacked formal, written procedures defining the quality unit's roles and responsibilities, particularly for its multi-site operations spanning Illinois and Pennsylvania. Deficiencies were noted in establishing clear communication pathways, testing, release, and approval authorities between sites, and in having proper controls for in-process materials transferred between facilities. Critically, quality agreements were missing, and the firm failed to ensure proper notification of stability failures between its locations.

The inspection also revealed inadequate process validation procedures, specifically failing to identify and evaluate shipping conditions for in-process drug products transferred between facilities as a critical process step. Lastly, the company did not follow its own written procedures for segregating raw materials by release status, with instances of commingled released and unreleased materials observed in the warehouse. To ensure compliance with federal regulations, Frontida Biopharm is required to thoroughly address these observations and implement effective corrective actions.

Company
Frontida Biopharm, LLC
Inspection date
October 24, 2025
Product type
drugs
Office
Chicago District Office
Person
  • Angela C. Welker
View Company Profile

ID · 74415777-b9cd-4f45-84e2-3efb3c5ee1b4

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Frontida Biopharm, LLC
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.